Other
Retinitis
0
Pipeline Programs↗
0
Active Trials↗
1
Companies Involved↗
Retinitis is an early-stage landscape with 0 programs across 1 company. The most active players are Roche.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
4
clinical trials
Completed3 · 75%
Unknown status1 · 25%
Clinical Trials
Trial Activity
HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000799·100 enrolled
Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT00000894·300 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)